FLOR RANGEL: Open Payments
NPI 1689392649 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$550 in 22 payments from 9 companies in 2025. Trend: 2023 $1,251 · 2024 $1,110 · 2025 $550
Food & beverage: $550
| Company | Payments | Amount |
|---|---|---|
| Dexcom, Inc. | 6 | $190 |
| Novo Nordisk Inc | 5 | $186 |
| Abbott Laboratories | 3 | $51 |
| AstraZeneca Pharmaceuticals LP | 2 | $34 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $28 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| TOLMAR, INC. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
Products named: DEXCOM G7 GSS (161), Ozempic, Dexcom G6 Transmitter, FARXIGA, XIFAXAN, Wegovy, JARDIANCE, PROCLAIM.
Industry payments across TX — which companies pay providers there.
